Barbosa-Silva TG, Bielemann RM, Gonzalez MC, Menezes AM Prevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of the COMO VAI? study. J Cachexia Sarcopenia Muscle. 2016 May;7(2):136-43. doi: 10.1002/jcsm.12049. Epub 2015 Jun 9. Erratum in: J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):503.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9. Epub 2013 Feb 8. Review. Erratum in: Lancet. 2013 Oct 19;382(9901):1328.
de van der Schueren MA, Wijnhoven HA, Kruizenga HM, Visser M A critical appraisal of nutritional intervention studies in malnourished, community dwelling older persons. Clin Nutr. 2016 Oct;35(5):1008-14. doi: 10.1016/j.clnu.2015.12.013. Epub 2015 Dec 29. Review.
Dijxhoorn DN, IJmker-Hemink VE, Wanten GJA, van den Berg MGA Strategies to increase protein intake at mealtimes through a novel high-frequency food service in hospitalized patients. Eur J Clin Nutr. 2019 Jun;73(6):910-916. doi: 10.1038/s41430-018-0288-6. Epub 2018 Aug 22.
Dos Santos L, Cyrino ES, Antunes M, Santos DA, Sardinha LB Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):245-250. doi: 10.1002/jcsm.12160. Epub 2016 Nov 8.
Hannan-Jones M, Capra S Developing a valid meal assessment tool for hospital patients. Appetite. 2017 Jan 1;108:68-73. doi: 10.1016/j.appet.2016.09.025. Epub 2016 Sep 22.
Hope K, Ferguson M, Reidlinger DP, Agarwal E "I don't eat when I'm sick": Older people's food and mealtime experiences in hospital. Maturitas. 2017 Mar;97:6-13. doi: 10.1016/j.maturitas.2016.12.001. Epub 2016 Dec 12.
Landi F, Picca A, Calvani R, Marzetti E Anorexia of Aging: Assessment and Management. Clin Geriatr Med. 2017 Aug;33(3):315-323. doi: 10.1016/j.cger.2017.02.004. Epub 2017 May 20. Review.
Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc. 2013 Jan;14(1):10-7. doi: 10.1016/j.jamda.2012.08.001. Epub 2012 Sep 13. Review.
Malmstrom TK, Morley JE SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013 Aug;14(8):531-2. doi: 10.1016/j.jamda.2013.05.018. Epub 2013 Jun 25.
Morley JE Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):523-526. doi: 10.1002/jcsm.12192. Epub 2017 Apr 27.
Morley JE Nutrition in the elderly. Curr Opin Gastroenterol. 2002 Mar;18(2):240-5.
Preston D, Nguyen TNM, Visvanathan R, Wilson A Nutrition and the community-dwelling older person: a pilot study in general practice. Int J Evid Based Healthc. 2018 Mar;16(1):73-80. doi: 10.1097/XEB.0000000000000124.
Roberts S, Desbrow B, Chaboyer W Feasibility of a patient-centred nutrition intervention to improve oral intakes of patients at risk of pressure ulcer: a pilot randomised control trial. Scand J Caring Sci. 2016 Jun;30(2):271-80. doi: 10.1111/scs.12239. Epub 2015 Jun 2.
Vasse E, Beelen J, de Roos NM, Janssen N, de Groot LC Protein intake in hospitalized older people with and without increased risk of malnutrition. Eur J Clin Nutr. 2018 Jun;72(6):917-919. doi: 10.1038/s41430-018-0171-5. Epub 2018 May 15.
Weijzen MEG, Kouw IWK, Geerlings P, Verdijk LB, van Loon LJC During Hospitalization, Older Patients at Risk for Malnutrition Consume <0.65 Grams of Protein per Kilogram Body Weight per Day. Nutr Clin Pract. 2020 Aug;35(4):655-663. doi: 10.1002/ncp.10542. Epub 2020 Jun 24.
Does the Nutritionist's Educational Intervention Influence Protein Intake in Hospitalized Elderly People?
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.